Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) Yale University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000319

Purpose

The purpose of this study is to evaluate the efficacy of treating opioid-dependent individuals with buprenorphine on a thrice-weekly schedule compared to daily dosing.

Condition	Intervention	Phase
Opioid-Related Disorders Substance-Related Disorders	Drug: Buprenorphine	Phase II

Drug Information available for: Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Buprenorphine Maintenance Dose Schedule and Treatment Setting

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Depression
Withdrawal symptoms
Opioid and cocaine use
Social and psychological functioning
AIDS risk behavior
Opiate withdrawal symptoms

Estimated Enrollment:	0
Study Start Date:	June 1996

Eligibility

Ages Eligible for Study:	21 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000319

Locations

United States, Connecticut
APT Residential Services Division
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Yale University

Investigators

Principal Investigator:

Richard Schottenfeld, M.D.

Yale University

More Information

Study ID Numbers:	NIDA-09803-2, R01-09803-2
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000319
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Buprenorphine
Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin
Opioid-Related Disorders

Additional relevant MeSH terms:

Disease
Physiological Effects of Drugs
Narcotic Antagonists
Central Nervous System Depressants
Narcotics
Pharmacologic Actions
Pathologic Processes

Sensory System Agents
Therapeutic Uses
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on January 15, 2009